An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

Cancer Cell

Volumn 29, Issue 1, 2016, Pages 104-116

  Hakimi, A Ari ^a   Reznik, Ed ^a   Lee, Chung Han ^a   Creighton, Chad J ^b   Brannon, A Rose ^a   Luna, Augustin ^a   Aksoy, B Arman ^a   Liu, Eric Minwei ^a   Shen, Ronglai ^a   Lee, William ^a   Chen, Yang ^c   Stirdivant, Steve M ^c   Russo, Paul ^a   Chen, Ying Bei ^a   Tickoo, Satish K ^a   Reuter, Victor E ^a   Cheng, Emily H ^a   Sander, Chris ^a   Hsieh, James J ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c METABOLON INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FOLIC ACID; GLUTATHIONE; METHIONINE; POLYAMINE; TRANSCRIPTOME; UREA; TUMOR MARKER;

ADULT; AGED; AMINO ACID METABOLISM; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER GROWTH; CARBON METABOLISM; CARCINOGENESIS; CELL METABOLISM; CENTRAL CARBON METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLATE METABOLISM; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METABOLOME; METABOLOMICS; METASTASIS; MOLECULAR PATHOLOGY; ONE CARBON METABOLISM; POLYAMINE METABOLISM; PRIORITY JOURNAL; TRANSCRIPTOMICS; UREA CYCLE; CANCER STAGING; CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; KIDNEY NEOPLASMS; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; METABOLOMICS; NEOPLASM STAGING; PROGNOSIS;

EID: 84958749958     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.12.004     Document Type: Article

References (52)

1. Anders S., McCarthy D.J., Chen Y., Okoniewski M., Smyth G.K., Huber W., Robinson M.D. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat. Protoc. 2013, 8:1765-1786.
2. Budhu A., Roessler S., Zhao X., Yu Z., Forgues M., Ji J., Karoly E., Qin L.X., Ye Q.H., Jia H.L., et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013, 144:1066-1075.e1.
3. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
4. Casero R.A., Marton L.J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 2007, 6:373-390.
5. Chubukov V., Uhr M., Le Chat L., Kleijn R.J., Jules M., Link H., Aymerich S., Stelling J., Sauer U. Transcriptional regulation is insufficient to explain substrate-induced flux changes in Bacillus subtilis. Mol. Syst. Biol. 2013, 9:709.
6. Commisso C., Davidson S.M., Soydaner-Azeloglu R.G., Parker S.J., Kamphorst J.J., Hackett S., Grabocka E., Nofal M., Drebin J.A., Thompson C.B., et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497:633-637.
7. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
8. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
9. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
10. Fan J., Ye J., Kamphorst J.J., Shlomi T., Thompson C.B., Rabinowitz J.D. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014, 510:298-302.
11. Funakoshi T., Lee C.H., Hsieh J.J. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat. Rev. 2014, 40:533-547.
12. Gall W.E., Beebe K., Lawton K.A., Adam K.P., Mitchell M.W., Nakhle P.J., Ryals J.A., Milburn M.V., Nannipieri M., Camastra S., et al. alpha-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010, 5:e10883.
13. Gatto F., Nookaew I., Nielsen J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc. Natl. Acad. Sci. USA 2014, 111:E866-E875.
14. Gaujoux R., Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 2010, 11:367.
15. Gebhard R.L., Clayman R.V., Prigge W.F., Figenshau R., Staley N.A., Reesey C., Bear A. Abnormal cholesterol metabolism in renal clear cell carcinoma. J. Lipid Res. 1987, 28:1177-1184.
16. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
17. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005, 5:857-866.
18. Hakimi A.A., Furberg H., Zabor E.C., Jacobsen A., Schultz N., Ciriello G., Mikklineni N., Fiegoli B., Kim P.H., Voss M.H., et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J. Natl. Cancer Inst. 2013, 105:1862-1870.
19. Hakimi A.A., Pham C.G., Hsieh J.J. A clear picture of renal cell carcinoma. Nat. Genet. 2013, 45:849-850.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
21. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
22. Hu J., Locasale J.W., Bielas J.H., O'Sullivan J., Sheahan K., Cantley L.C., Vander Heiden M.G., Vitkup D. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 2013, 31:522-529.
23. Huang Q., Tan Y., Yin P., Ye G., Gao P., Lu X., Wang H., Xu G. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013, 73:4992-5002.
24. Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013, 27:2179-2191.
25. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 2004, 10:6290S-6295S.
26. Kaelin W.G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 2008, 8:865-873.
27. Kaelin W.G., McKnight S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153:56-69.
28. Kimmelman A.C. Metabolic dependencies in RAS-driven cancers. Clin. Cancer Res. 2015, 21:1828-1834.
29. Law C.W., Chen Y., Shi W., Smyth G.K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014, 15:R29.
30. Lee D.D., Seung H.S. Learning the parts of objects by non-negative matrix factorization. Nature 1999, 401:788-791.
31. Li B., Qiu B., Lee D.S., Walton Z.E., Ochocki J.D., Mathew L.K., Mancuso A., Gade T.P., Keith B., Nissim I., et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 2014, 513:251-255.
32. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 2010, 7:277-285.
33. Lu S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999, 13:1169-1183.
34. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell. 2010, 40:294-309.
35. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., Guarente L., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
36. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
37. Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481:385-388.
38. Nogueira V., Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin. Cancer Res. 2013, 19:4309-4314.
39. Owen O.E., Kalhan S.C., Hanson R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 2002, 277:30409-30412.
40. Prabhu A., Sarcar B., Kahali S., Yuan Z., Johnson J.J., Adam K.P., Kensicki E., Chinnaiyan P. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res. 2014, 74:787-796.
41. Raimundo N., Baysal B.E., Shadel G.S. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol. Med. 2011, 17:641-649.
42. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 2012, 11:709-730.
43. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 2013, 123:3664-3671.
44. Settembre C., Ballabio A. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol. 2014, 24:743-750.
45. Son J., Lyssiotis C.A., Ying H., Wang X., Hua S., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496:101-105.
46. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
47. Thiele I., Swainston N., Fleming R.M., Hoppe A., Sahoo S., Aurich M.K., Haraldsdottir H., Mo M.L., Rolfsson O., Stobbe M.D., et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 2013, 31:419-425.
48. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
49. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
50. Wakabayashi N., Itoh K., Wakabayashi J., Motohashi H., Noda S., Takahashi S., Imakado S., Kotsuji T., Otsuka F., Roop D.R., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 2003, 35:238-245.
51. Wei E.Y., Hsieh J.J. A river model to map convergent cancer evolution and guide therapy in RCC. Nat. Rev. Urol. 2015, 12:706-712.
52. Wise D.R., Ward P.S., Shay J.E., Cross J.R., Gruber J.J., Sachdeva U.M., Platt J.M., DeMatteo R.G., Simon M.C., Thompson C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 2011, 108:19611-19616.